Hypermarcas Profit Climbs 24% on Pharmaceutical Sales

Hypermarcas SA (HYPE3), the Brazilian maker of more than 190 consumer products, said profit climbed 24 percent after sales of pharmaceuticals rose.

Net income increased to 40.8 million reais ($21.2 million) from 32.9 million reais a year earlier, the Sao Paulo-based company said in a regulatory filing May 5. The profit missed a 53.9 million-real mean estimate for adjusted net income of eight analysts compiled by Bloomberg.

Sales advanced 14 percent to 897.1 million reais, pushed by a 17 percent increase at its pharmaceutical unit and a rise of 9.2 percent at its consumer products division.

“In 2012, the company will maintain its focus on organic growth combined with operating cash generation and the reduction of debt levels,” the company said in the statement.

Hypermarcas has gained 41 percent since the beginning of the year, the third-best performer in the Bovespa benchmark index.

To contact the reporters on this story: Fabiola Moura in Sao Paulo at fdemoura@bloomberg.net; Carlos Caminada in Sao Paulo at ccaminada1@bloomberg.net

To contact the editor responsible for this story: Helder Marinho at hmarinho@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.